Skip to content

Study · Measured the body's own peptide · 2012

3 results

Plasma Kisspeptin-54 levels in gastric cancer patients.

Ergen A, Canbay E, Bugra D, Zeybek U, Yamaner S, Bulut T

International journal of surgery (London, England)5 Sept 2012Cited by 2 (Europe PMC)

PMID22959969 (opens in a new tab)DOI10.1016/j.ijsu.2012.08.014 (opens in a new tab)PepBankPUB-22959969
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

No result from this study comes from a test of the peptide.

Natural levels measured3

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

  1. 01HumanEndogenous levelObservational studyOther

    In patients with gastric cancer, plasma kisspeptin‑54 levels were significantly higher than in controls.

    In plain wordsIn people with gastric cancer, the body's own kisspeptin‑54 levels in blood were higher than in controls.

    Peptide
    Kisspeptin-54 (metastin)
    Outcome
    IncreasePlasma KP-54 in gastric cancer patients versus controls
    Study

    n = 99

    Comparator
    Age-matched controls
    Outcome group
    Tumor growth · Cancer

    Measurements

    Plasma KP-54
    63.3
    GC patients
    Plasma KP-54
    49
    controls

    Source sentences

    Summary
    Plasma KP-54 levels were significantly higher in GC patients (63.3±17.9) than in controls (49.0±12.7) (p=0.000).
    1 context sentence
    Summary · context
    Plasma KP-54 levels were quantified with enzyme-immunoassay from blood samples of 40 patients with GC at their initial staging and 59 age-matched controls.

    This result measures the body's own Kisspeptin-54 (metastin). Nobody was given the peptide. It is not evidence about taking it.

  2. 02HumanEndogenous levelObservational studyOther

    Plasma kisspeptin‑54 at a cut-off of 44 ng/ml had a sensitivity of 60% and a specificity of 78% for gastric cancer.

    In plain wordsIn people with gastric cancer, the body's own kisspeptin‑54 level in blood showed modest accuracy for telling patients from controls.

    Peptide
    Kisspeptin-54 (metastin)
    Outcome
    Not applicableDiagnostic accuracy of plasma KP-54 for gastric cancer
    Study

    n = 99

    Outcome group
    Tumor growth · Cancer

    Measurements

    Cut-off
    44 ng/ml
    KP-54
    Sensitivity
    60%
    cut-off 44 ng/ml
    Specificity
    78%
    cut-off 44 ng/ml
    Positive predictive value
    63%
    cut-off 44 ng/ml
    Negative predictive value
    74%
    cut-off 44 ng/ml

    Source sentences

    Summary
    Cut-off value for KP-54 was determined as 44 ng/ml and sensitivity, specificity, positive predictive value and negative predictive value, were 60%, 78%, 63%, and 74% respectively.
    1 context sentence
    Summary · context
    Plasma KP-54 levels were quantified with enzyme-immunoassay from blood samples of 40 patients with GC at their initial staging and 59 age-matched controls.

    This result measures the body's own Kisspeptin-54 (metastin). Nobody was given the peptide. It is not evidence about taking it.

  3. 03HumanEndogenous levelObservational studyOther

    In patients with gastric cancer, plasma kisspeptin‑54 levels were not correlated with any clinicopathological feature.

    In plain wordsIn people with gastric cancer, the body's own kisspeptin‑54 levels were not linked to any tumour feature studied.

    Peptide
    Kisspeptin-54 (metastin)
    Outcome
    No significant changeCorrelation of plasma KP-54 with clinicopathological features
    Study

    n = 40

    Outcome group
    Tumor growth · Cancer

    Source sentences

    Summary
    Plasma KP-54 levels were not correlated with any clinicopathological features of GC patients (p>0.05).
    1 context sentence
    Summary · context
    Plasma KP-54 levels were quantified with enzyme-immunoassay from blood samples of 40 patients with GC at their initial staging and 59 age-matched controls.

    This result measures the body's own Kisspeptin-54 (metastin). Nobody was given the peptide. It is not evidence about taking it.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.